2022 HPV HEAD & NECK FORUM
Available soon
HPV HEAD & NECK FORUM
Sunday, May 30, 2021
Coordinators: E. Rettig (USA), J. P. Klussmann (Germany)
The EUROGIN HPV and Head & Neck Cancer Forum highlights recent advances and areas of active research in the field of HPV-related head and neck cancers. This year’s Forum features the emerging role of biomarkers in screening and management of HPV-related oropharyngeal cancer, updates from deintensification trials and other therapeutic innovations, and a dedicated session focusing on molecular & immunologic considerations.
A dedicated debate session will focus on the controversies regarding the impact of HPV infection on oro-pharyngeal cancer, including diagnosis, management and decision making.
Overview of Sessions
Subject to change
Epidemiology & Screening
Chair: T. Waterboer (Germany), U. Wieland (Germany)
9:00 - 10:30
- Biomarkers for HPV-OPC • E. Prigge (Germany)
- Familial occurence of OPSCC and other HPV-associated cancers • K. Hemminki (Germany)
- Screening for HPV-OPC: Overview of screening concepts • H. Robbins (France)
- Risk-stratified screening of OPSCC - Proof of concept trial • M. Lehtinen (Sweden)
- Cost-effectiveness of OPSCC elimination • S. Vänskä (Sweden)
Management & Surveillance
Chair: P. Bossi (Italy), A. Psyrri (Greece)
10:45 - 12:15
- Biomarker-based surveillance in HPV-associated OSCC • M. Broglie Däppen (Switzerland)
- Work up of unknown primary • A. Arora (UK)
- Updates in deintensification • C. J. Busch (Germany)
- Impact of deintensification on HRQOL outcomes • C. Simon (Switzerland)
- High-risk & recurrent disease • H. Mehanna (UK)
- Surgical deintensification • T. Jones (UK)
Submitted papers I
Chair: J. P. Klussmann (Germany)
12:30 - 13:15
Molecular & Immunologic considerations
Chair: E.-J. Speel (Netherlands), J. Klozar (Czech Republic)
14:00 -15:30
- HPV viral integration • S. Virani (France)
- Molecular modifiers of prognosis in HPV-OPC • L. Licitra (Italy)
- Role of biomarkers in HPV-OPC treatment • N. Wuerdeman (Germany)
- Immune microenvironment in HPV-OPC • T. Dalianis (Sweden)
- HPV-specific T cell response • S. Van der Burg (Netherlands)
- Enhancing Immune Response to HPV-OPC with Cell-based Tumor Vaccines • O. Rosen (USA)
Submitted paper II
Chair: H. Mehanna (UK)
15:45 - 17:15
EUROGIN (EUropean Research Organisation on Genital Infection and Neoplasia) brings together clinicians and scientists whose work is related to genital infections and neoplasia.
TRUSTED PARTNER
